News

Veru completes enrollment in Phase 2b PLATEAU Trial testing enobosarm with semaglutide in older adults with severe obesity.

Oral semaglutide reduced heavy drinking days and alcohol cravings in an eight-week randomized trial for alcohol use disorder, with...

CLN-049 advances to registrational Phase 2 study in relapsed/refractory AML following FDA's End-of-Phase 1 meeting with Cullinan Therapeutics.

Atea's bemnifosbuvir/ruzasvir achieved non-inferiority in Phase 3 Hepatitis C trial, offering eight-week treatment for non-cirrhotic patients versus twelve week

ICH E6(R3) redistributes data governance accountability between sponsors and sites, formalizing joint responsibility for trial data integrity.

SaaS clinical trial software market projected for 17.14% annual growth, democratizing access to research infrastructure for smaller sites.

Pacira completes manufacturing transition in PCRX-201 Phase 2 trial without enrollment delays, using commercial process aligned with registration plans.

Akeso doses first patient in AK138D1 + ivonescimab Phase Ib/II lung cancer study combining HER3 ADC with PD-1/VEGF bispecific...

Oryzon's iadademstat shows 78% CR rate in AML patients with TP53 and RAS mutations, addressing historically treatment-resistant genomic subgroups.

MapLight's ML-007C-MA met its primary endpoint in Phase 2 schizophrenia trial, showing significant PANSS improvement and cognitive benefits with...